Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prince Pharmaceutical CoROCO:6935 +4.59%62 EV-to-EBITDA is 6.00 as of Sep. 03, 2026, which is 60% below its 10-year median of 14.88. GuruFocus rates ROCO:6935 with a GF Score™ of 62/100 and a GF Value™ of NT$42.37 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 727 Drug Manufacturers companies, Prince Pharmaceutical Co ranks better than 80.74% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Prince Pharmaceutical Co's enterprise value is NT$1,301 Mil.
Prince Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$217 Mil. Therefore, Prince Pharmaceutical Co's EV-to-EBITDA for today is 6.00.
The historical rank and industry rank for Prince Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
ROCO:6935'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.78 Med: 14.88 Max: 79.41
Current: 6.01
During the past 7 years, the highest EV-to-EBITDA of Prince Pharmaceutical Co was 79.41. The lowest was 5.78. And the median was 14.88.
ROCO:6935's EV-to-EBITDA is ranked better than 80.74% of 727
companies
in the Drug Manufacturers industry
Industry Median: 13.53
vs ROCO:6935: 6.01
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Prince Pharmaceutical Co (ROCO:6935) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prince Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Prince Pharmaceutical Co's share price for today is NT$29.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prince Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$3.445.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Prince Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prince Pharmaceutical Co EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prince Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Prince Pharmaceutical Co's EV-to-EBITDA falls into.
Prince Pharmaceutical Co's current Enterprise Value is NT$1,301 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Prince Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$217 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prince Pharmaceutical Co (ROCO:6935) has a EV-to-EBITDA of 6.00 as of Sep. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Prince Pharmaceutical Co. This is 60% below median its historical median of 14.88. Over the past decade, Prince Pharmaceutical Co's EV-to-EBITDA has ranged from 5.78 to 79.41. According to the industry distribution chart, Prince Pharmaceutical Co ranks #140 out of 727 companies in the Drug Manufacturers industry, placing it in the top 19.3%.
Is Prince Pharmaceutical Co's EV-to-EBITDA too high?
Prince Pharmaceutical Co's current EV-to-EBITDA of 6.00 is 60% below median its 10-year median of 14.88. Over the past 10 years, this metric has ranged from a low of 5.78 to a high of 79.41. The Drug Manufacturers industry median EV-to-EBITDA is 13.53. Prince Pharmaceutical Co's value of 6.00 is 55.7% below this industry median. Based on the distribution chart, Prince Pharmaceutical Co ranks #140 out of 727 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Prince Pharmaceutical Co has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prince Pharmaceutical Co's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Prince Pharmaceutical Co ranks #140 out of 727 companies for EV-to-EBITDA. This places Prince Pharmaceutical Co in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.53. Prince Pharmaceutical Co's value of 6.00 is 55.7% below this benchmark. Historically, Prince Pharmaceutical Co's own EV-to-EBITDA has ranged from 5.78 to 79.41 over the past decade. While the company's 10-year median is 14.88 vs. the industry median of 13.53, Prince Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.53, based on 727 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prince Pharmaceutical Co's current EV-to-EBITDA of 6.00 is 55.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Prince Pharmaceutical Co. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prince Pharmaceutical Co's current EV-to-EBITDA is 6.00, which is 60% below median its own 10-year median of 14.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prince Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Prince Pharmaceutical Co (ROCO:6935) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$42.37, compared to a current price of NT$29.60 — trading 30.1% below its estimated fair value. The current EV-to-EBITDA is 6.00, which is 60% below median its 10-year median of 14.88 and 55.7% below the Drug Manufacturers industry median of 13.53. Prince Pharmaceutical Co's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Prince Pharmaceutical Co (ROCO:6935), the current EV-to-EBITDA is 6.00 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prince Pharmaceutical Co (ROCO:6935) Overvalued in 2026?
Based on GuruFocus' analysis, Prince Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$29.60 is trading 30.1% below its estimated GF Value™ of NT$42.37.
GuruFocus considers Prince Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for ROCO:6935:
EV-to-EBITDA: 6.00 (60% below median its 10-year median of 14.88)
GF Value™: NT$42.37 vs. price of NT$29.60 (30.1% below fair value)
Industry Position: 55.7% below the Drug Manufacturers median (#140 of 727)
No single metric tells the full story. See the ROCO:6935 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prince Pharmaceutical Co Ltd is engaged in the manufacturing, packaging, processing, and trading of various active pharmaceutical ingredients and health supplements. The company supplies its products to Taiwan, Japan, Spain, Europe and other regions.
62GF Score
Get the complete analysis for ROCO:6935
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6935 has been successfully added to your 
